ChromaDex (NASDAQ:CDXC – Get Rating) had its price target reduced by HC Wainwright from $7.00 to $5.50 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.
A number of other equities research analysts have also issued reports on CDXC. B. Riley lowered shares of ChromaDex from a buy rating to a neutral rating and decreased their target price for the company from $6.00 to $2.40 in a research note on Thursday, August 11th. Oppenheimer lowered shares of ChromaDex from an outperform rating to a market perform rating in a research note on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of Hold and an average price target of $5.48.
Get
ChromaDex alerts:
ChromaDex Stock Down 2.0 %
Shares of NASDAQ:CDXC opened at $1.45 on Monday. The firm has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.04. The firm has a market capitalization of $99.10 million, a P/E ratio of -3.54 and a beta of 1.71. ChromaDex has a 12-month low of $1.44 and a 12-month high of $8.75.
ChromaDex (NASDAQ:CDXC – Get Rating) last issued its earnings results on Wednesday, August 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative net
margin of 41.01% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($0.08) EPS. Equities research analysts expect that ChromaDex will post -0.31 earnings per share for the current fiscal year.
Insider Activity at ChromaDex
In other ChromaDex news, major shareholder Hoi Shuen Solina Holly Chau acquired 60,037 shares of ChromaDex stock in a transaction that occurred on Thursday, June 16th. The stock was acquired at an average price of $1.66 per share, with a total value of $99,661.42. Following the purchase, the insider now owns 6,925,641 shares in the company, valued at $11,496,564.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.80% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. ProShare Advisors LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. Merriman Wealth Management LLC bought a new position in ChromaDex in the 1st quarter worth $29,000. Keebeck Alpha LP bought a new position in ChromaDex in the 4th quarter worth $56,000. Finally, XTX Topco Ltd bought a new position in ChromaDex in the 1st quarter worth $76,000. Institutional investors own 29.64% of the company's stock.
About ChromaDex
(Get Rating)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Macy's Value Lies Beneath its Stores
- The Mattel Train is Ready to Leave the Station
- 3 WallStreetBets Stocks Wall Street is (Mostly) Bullish On
- Does Micron's Dividend Increase Mean It's Time To Buy?
- What is the NASDAQ Stock Exchange?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
